Meta-Analysis:
Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies
Metrics: PDF 835 views | HTML 864 views | ?
Abstract
Dong Li1 and Heinv Yang1
1Department of Cardiac and Thoracic Surgery, Weihai Central Hospital, Weihai 264400, China
Correspondence to:
Heinv Yang, email: [email protected]
Keywords: metabolic syndrome; lung cancer; cohort study; meta-analysis
Received: July 25, 2017 Accepted: August 23, 2017 Published: March 01, 2018
ABSTRACT
Background: Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer.
Materials and Methods: Relevant cohort studies were identified by searching of PubMed and Embase databases. Cochrane’s Q test and I2 statistic were used to analyze the heterogeneity. Random effect model was used for the meta-analysis.
Results: Five cohort studies with 188,970 participants and 1,295 lung cancer cases during follow-up were included. No significant association between MetS and lung cancer incidence was found in studies that MetS was defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I2 = 0), or IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I2 = 0). Results were consistent in male and female participants, or in those smoking status was adjusted (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I2 = 0). Sensitivity analyses omitting one study at a time did not significantly change the results. No publication bias was detected based on the Egger regression test (p = 0.32).
Conclusions: Presence of MetS does not significantly influence the subsequent incidence of lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24565